VistaGen reports Phase 3 fasedienol shows positive efficacy signal in severe social anxiety subgroup analysis
PUBT · 2d ago
Share
Listen to the news
- VistaGen set a Psych Congress 2026 poster for Sept. 17-18 in New Orleans on Phase 3 fasedienol nasal spray data.
- Results have not been presented yet; the company plans to disclose subgroup analyses at the meeting.
- Data highlight a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder.
- Readout targets acute treatment positioning, supporting the investment case for its lead intranasal pherine program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100830PRIMZONEFULLFEED9824302) on September 10, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending